<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03284853</url>
  </required_header>
  <id_info>
    <org_study_id>PG324-CS303</org_study_id>
    <nct_id>NCT03284853</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Prospective, Double-masked, Randomized, Multicenter, Active-controlled, Parallel-group, 6-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to GANFORT® (Bimatoprost 0.03% / Timolol 0.5%) Ophthalmic Solution in Subjects With Elevated Intraocular Pressure (MERCURY 3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aerie Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aerie Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02%
      / 0.005% Ophthalmic Solution, relative to GANFORT® for lowering of intraocular pressure (IOP)
      in patients with elevated intraocular pressure
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 5, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean diurnal Intraocular Pressure by Goldmann Applanation Tonometry</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of anterior segment tissues by slit lamp biomicroscopy</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of posterior segment tissues by dilated ophthalmoscopy</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic safety of vital signs (heart rate/bpm)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic safety of vital signs (blood pressure/systolic diastolic mmHg)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic safety clinical laboratory assessments (hematology and clinical chemistry)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Intraocular Pressure</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">472</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Netarsudil/Latanoprost 0.02%/0.005%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PG324 Ophthalmic Solution (netarsudil 0.02% / latanoprost 0.005%) one drop daily to each eye for 180 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GANFORT®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic solution one drop daily to each eye for 180 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Netarsudil/Latanoprost 0.02%/0.005%</intervention_name>
    <description>Topical sterile ophthalmic solution</description>
    <arm_group_label>Netarsudil/Latanoprost 0.02%/0.005%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GANFORT®</intervention_name>
    <description>Topical sterile ophthalmic solution</description>
    <arm_group_label>GANFORT®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must be 18 years or older

          2. Diagnosis of Open Angle Glaucoma or Ocular Hypertension

          3. Participants insufficiently controlled and/or considered in need for combination
             therapy

          4. Medicated intraocular pressure (IOP) greater than or equal to 17 mmHg and less than 28
             mmHg in both eyes at screening visit

          5. Unmedicated (post-washout) IOP greater than 20mmHg in at least one eye and less than
             36mmHg in both eyes at two qualification visits. At 2nd qualification visit to have
             IOP greater than 17mmHg in at least one eye and less than 36mmHg in both eyes. If only
             one eye qualifies at 2nd qualification visit it MUST be the same eye qualified on the
             1st visit (this will be known as the study eye).

          6. Best corrected visual acuity +1.0 logMAR or better

          7. Be willing and able to give informed consent and follow instructions

          8. Women must be either of non-child bearing potential, or women with child bearing
             potential and men with reproductive potential must be willing to practice acceptable
             methods of birth control during the study

          9. Women of child bearing potential must have a negative urine pregnancy test within 7
             days of first dose of study treatment and agree to use highly effective contraception
             from time of randomization and for 3 months after last dose of study medication

         10. Men with a female partner of childbearing potential must have either had a prior
             vasectomy or agree to use effective contraception from time of randomization and for 3
             months following the last dose of study medication

         11. In France, a subject will be eligible for inclusion in this study only if either
             affiliated to or as a beneficiary of a social security number

        Exclusion Criteria:

        Ophthalmic

          1. Clinically significant ocular disease which might interfere with interpretation of the
             study results, including subjects with glaucomatous damage so severe that washout of
             ocular hypotensive medication for four weeks or longer would not be judged as safe

          2. Pseudoexfoliation or pigment dispersion glaucoma, history of narrow angles or angle
             closure glaucoma. Previous laser peripheral iridotomy is not permitted

          3. IOP (NOTE - fixed dose combinations, for the purpose of this exclusion criterion count
             as one medication); however subjects currently taking 2 fixed dose combination
             products are excluded.

          4. Treatment-naïve subjects

          5. Prior treatment with GANFORT® topical eye drops, where subjects IOP did not achieve
             target IOP and was considered a failure or an insufficient response. Subjects
             currently (prior to screening visit) being treated with GANFORT® are excluded from the
             study.

          6. Known hypersensitivity to any component of the investigational formulations to be used

          7. Previous glaucoma intra ocular surgery

          8. Refractive surgery in either eye

          9. Ocular trauma within 6 months prior to screening, or ocular surgery or non- refractive
             laser treatment within 3 months prior to screening

         10. Recent or current evidence of ocular infection or inflammation in either eye.

         11. Use of ocular medication in either eye within 30 days of screening and throughout the
             study with the exception of permitted ocular medication (which must be the same
             medication for 30 days prior to screening) as prescribed by the investigator

         12. Mean central corneal thickness greater than 620μm at screening

         13. Any abnormality preventing reliable Goldmann applanation tonometry of either eye

             Systemic

         14. Clinically significant abnormalities in laboratory tests at screening

         15. Known hypersensitivity or contraindication to GANFORT® and to β-adrenoceptor
             antagonists

         16. Clinically significant systemic disease which might interfere with the study

         17. Participation in any investigational study within 30 days prior to screening

         18. Systemic medication (including corticosteroids) that could have a substantial effect
             on IOP which HAVE NOT been maintained at a consistent dose and regime within 30 days
             prior to screening, and are anticipated to change in dose and/or regime during the
             study

         19. Use of topical steroids containing medications on the face or in or around the eyes
             will exclude the subject

         20. Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or
             not using a medically acceptable and highly effective form of birth control

         21. Vulnerable subjects such as minors, adults under legal protection or unable to express
             their consent, persons deprived of liberty or persons subject to psychiatric care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Senchyna</last_name>
    <role>Study Director</role>
    <affiliation>Aerie Pharmaceuticals, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State Hospital - University Medical Center Academical Department of Ophthalmology</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albertgasse 39/10+11</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanusch Hospital</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Sint Rafael</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Brno Eye Department</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaucoma center Oční klinika VFN a 1. LF UK</name>
      <address>
        <city>Praha</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Service Centre Francois Xavier Michelet CHU Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre ophtalmologique Pole vision val d'ouest</name>
      <address>
        <city>Ecully</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Service - Batiment R Hospital de la Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes-Hospital Hotel Dieu Ophthalmology Service</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology department Necker University Hospital-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology Clinical Johannes Gutenberg-University Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augenarztpraxis Dr. Andreas Bayer</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Praxis</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Eye Hospital Tuebingen, STC eyetrial at the center for Ophthalmolgy</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Budapest Retina Associates</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen, Clinical Center, Ophthalmology Department</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bugat Pal Hospital</name>
      <address>
        <city>Heves</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ganglion Medical Center</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Szeged, Department of Ophthalmology</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markusovszky University Teaching Hospital</name>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Clinic DiNOGMI University Hospital San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. Ophthalmology, San Raffaele Hospital</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Fatebenefratelli Sacco P.O.L.Sacco</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Santi Paolo e Carlo - Ophthalmic Clinic</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine and Surgery University of Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Se Ophthamic Clinic of the University of Pavia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Pisana Hospital of Cisanello</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G.B.Bietti Foundation - IRCCS</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senese University Hospital</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C.U Oculistica, Azienda Ospedaliero Universitaria, Città della Salute e della Scienza</name>
      <address>
        <city>Torino</city>
        <zip>10146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Eye Clinic Ospedale Maggiore</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Politecnico Gianbattista Rossi AOUI Ospedale Borgo Roma</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Signes Ozolinas Doctor Practice in Ophthalmology</name>
      <address>
        <city>Jelgava</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Latvian American Eye Centre (LAAC)</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.Stradins Clinical University Hospital, Ophthalmology Clinic</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riga East University hospital, In-patient Department &quot;Biķernieki&quot;, Ophthalmology Clinic</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professor K. Gibinski University Clinical Centre</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Diagnostics and Microsurgery of Glaucoma</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Institute of Medicine Klinika Okulistyki</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Clinic Jasne Blonia</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Oftalmologia Barraquer</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Catalunya Ophthalmology Department</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital QuironSalud Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala de retina (ICR) Glaucoma and Investigation Department</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General del S.A.S. de Jerez de la Frontera</name>
      <address>
        <city>Cádiz</city>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía de Córdoba/C.P.E Carlos Castilla del Pino</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Ojos de la Coruña</name>
      <address>
        <city>La Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena Ophthalmology Department</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Torrevieja Ophthalmology Department</name>
      <address>
        <city>Torrevieja</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FISABIO-Oftalmología Médica</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Department Hospital Universitario Rio Hortega</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa Zaragoza Ophthalmology department</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet Ophthalmology Department</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Grampian Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Trust</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Department, Queen Alexandra Hospital</name>
      <address>
        <city>Cosham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Cheshire Hospitals NHS Foundation Trust</name>
      <address>
        <city>Crewe</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Anglia NHS Foundation trust Hinchingbrooke Hospital</name>
      <address>
        <city>Huntingdon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's &amp; St Thomas' NHS Foundation Trust Glaucoma Research Area</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital NHS</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Eye Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital, King's College Hospital NHS</name>
      <address>
        <city>Sidcup</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospitals Sunderland NHS Foundation Trust Sunderland Eye Infirmary</name>
      <address>
        <city>Sunderland</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 29, 2017</study_first_submitted>
  <study_first_submitted_qc>September 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 15, 2017</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

